@Article{Ciura2016,
journal="Nutrition, Obesity \& Metabolic Surgery",
issn="2353-9437",
year="2016",
title="Obesity-related metabolic disturbances and quality of life in subjects diagnosed with schizophrenia treated with atypical neuroleptics",
abstract=" Introduction:  Weight gain and related metabolic disturbances are frequent side effects observed during treatment with atypical neuroleptics, most commonly with olanzapine and quetiapine. Weight gain may also deteriorate the  quality of  life and cause treatment discontinuation. However, the  use of  these neuroleptics in orodispensible tablet (ODT) form was related to lower frequency of  weight gain. Therefore, the  aim of  this study was to evaluate the  incidence of  weight gain and metabolic disturbances in patients with schizophrenia treated with classical tablet (SOT) and orodispensible (ODT) formulations of  olanzapine and quetiapine, and analyze the  relationship between the  occurrence of  these side effects and quality of  life and patient attitude to the  treatment depending on the  therapy used.   Material and methods:   A three-month questionnaire survey was performed by 400 psychiatrists from across Poland, during three consecutive outpatient visits. 4437 adult patients with schizophrenia treated with atypical neuroleptics for at least one month but not more than 12 months were enrolled.    Results:   Weight gain was significantly more common among patients treated with olanzapine than those treated with quetiapine (54.7% vs. 20%, p < 0.001 and 34.7% vs. 28.6%, p < 0.01, on visits 1 and 3, respectively), and was less frequently observed in patients treated with ODT formulations. The  prevalence of  hypertension and type 2 diabetes on the  treatment did not change significantly. Treatment with olanzapine regardless of  the  form used was associated with a  better quality of  life and a  more positive attitude of  the  patient towards the  treatment.   Conclusions : The  risk of  weight gain is greater during treatment with olanzapine than quetiapine. However, olanzapine use is associated with better quality of  life and a  more positive attitude of  the  patient towards the  treatment. The  use of  neuroleptics in the  ODT form may reduce the  risk of  weight gain but does not significantly affect the  quality of  life or the  attitude of  the  patient towards the  treatment.",
author="Ciura, Dariusz
and Chudek, Jerzy
and Olszanecka-Glinianowicz, Magdalena",
pages="8--20",
doi="10.5114/noms.2016.62637",
url="http://dx.doi.org/10.5114/noms.2016.62637"
}